Sign In to Request a Protocol
Sign In to Request a Protocol

CJC-1295 DAC (2 mg) + Ipamorelin (5 mg) Stack

  • Table of Contents

CJC-1295 DAC + Ipamorelin Research Information Guide​

CJC-1295 DAC is studied in research settings for its biological characteristics and potential applications. This information is provided for research and educational reference purposes only.

  • CJC-1295 DAC: Add 2.0 mL bacteriostatic water → 1.0 mg/mL; inject once weekly.
  • Ipamorelin: Add 3.0 mL bacteriostatic water → 1.67 mg/mL; inject once daily.
  • Easy measuring: CJC-1295 DAC: 1 unit = 10 mcg; Ipamorelin: 1 unit ≈ 16.7 mcg on U-100 syringes.
  • Storage: Lyophilized: ≤−15 °C (5 °F); reconstituted: 2–8 °C (35.6–46.4 °F); use within 3–4 weeks.

This Research information is provided for general educational and research reference only. CJC-1295 DAC and Ipamorelin are included here as part of a general Research information guide. This content is not intended as medical advice, treatment guidance, or usage instruction. For Research-specific details, availability, or additional information, please contact us on Telegram.

  • Research Information Guide

General educational reference for CJC-1295 DAC + Ipamorelin Research information

CJC-1295 DAC Research Information

Research Overview: This information is provided for general educational and research reference only. CJC-1295 DAC is included here as part of a general Research information guide.

PhaseWeekly Daily Blend (mg)Volume (mL)Frequency
Standard1000 mcg (1.0 mg)100 units (1.0 mL)Once weekly
Aggressive2000 mcg (2.0 mg)100 units × 2 (2.0 mL total)Once weekly (split)

Note: This information is provided for general research and educational reference only. Specific usage details and measurement information are not included.

CJC-1295 DAC Research Information Notes

  • 1. Review the provided information or packaging details for general reference.
  • 2. For Research-specific details, please contact us on Telegram.
  • 3. For preparation-related information, please contact us directly.
  • 4. This content is provided for general educational and research reference only.

Ipamorelin Research Information

Reconstitution: 3.0 mL bacteriostatic water → 1.67 mg/mL (1666.7 mcg/mL) → 16.67 mcg per unit

PhaseDaily Blend (mg)Volume (mL)Frequency
Weeks 1–2 (Initiation)100 mcg6 units (0.06 mL)Once daily
Weeks 3–4 (Titration)150 mcg9 units (0.09 mL)Once daily
Weeks 5+ (Maintenance)200 mcg12 units (0.12 mL)Once daily
Aggressive (Optional)300 mcg18 units (0.18 mL)Once daily or split 2×/day

For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Ipamorelin Research Information Steps

  • 1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2. Inject slowly down the vial wall; avoid foaming.
  • 3. Gently swirl/roll until dissolved (do not shake).
  • 4. Label with date and refrigerate at 2–8 °C (35.6–46.4 °F).

Combined Stack Schedule — Standard Approach

Reconstitution: 3.0 mL bacteriostatic water → 1.67 mg/mL (1666.7 mcg/mL) → 16.67 mcg per unit

WeekCJC-1295 DAC (Weekly)Ipamorelin (Daily)
Weeks 1–21000 mcg (100 units) once weekly100 mcg (6 units) once daily
Weeks 3–41000 mcg (100 units) once weekly150 mcg (9 units) once daily
Weeks 5–121000 mcg (100 units) once weekly200 mcg (12 units) once daily
Timing: CJC-1295 DAC is typically administered on a fixed day each week. Ipamorelin is commonly administered before bed to coincide with natural nocturnal GH pulses.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Research Information

This section is provided for general educational and research reference only. For specific details, preparation information, or availability, please contact us on Telegram.

  • CJC-1295 DAC Vials (2 mg each):
  • 8 weeks ≈ Research information available
  • 12 weeks ≈ 6 vials
  • 16 weeks ≈ 8 vials
  • Ipamorelin Vials (5 mg each):
  • 8 weeks ≈ 3 vials (1 vial ≈ 25 days at 200 mcg/day)
  • 12 weeks ≈ 4 vials
  • 16 weeks ≈ 5 vials
  • Insulin Syringes (U-100):
  • Per week: 1 (CJC) + 7 (Ipamorelin) = 8 syringes
  • 8 weeks: 64 syringes
  • 12 weeks: 96 syringes
  • 16 weeks: 128 syringes

For Ipamorelin Research≤10 units, 30- or 50-unit syringes improve accuracy.

  • Bacteriostatic Water (10 mL bottles):
  • 8 weeks: CJC (4 × 2 mL) + Ipam (3 × 3 mL) = 17 mL → 2 × 10 mL bottles
  • 12 weeks: CJC (6 × 2 mL) + Ipam (4 × 3 mL) = 24 mL → 3 × 10 mL bottles
  • 16 weeks: CJC (8 × 2 mL) + Ipam (5 × 3 mL) = 31 mL → 4 × 10 mL bottles
  • Alcohol Swabs:

Per week: ~16 swabs (2/day for Ipamorelin + 2 for CJC weekly)

  • 8 weeks: 128 swabs → 2 × 100-count boxes
  • 12 weeks: 192 swabs → 2 × 100-count boxes
  • 16 weeks: 256 swabs → 3 × 100-count boxes
  • Protocol Overview

Concise summary of general research information for educational and research reference only.

  • Research Details: This information is provided for general educational reference only.
  • Research Reference: This content is not intended as medical advice, treatment guidance, or usage instruction.
  • Availability: For specific details or availability, please contact us on Telegram.
  • Storage: Please follow the provided label or packaging instructions for proper storage.
  • Research Information

Suggested overview for the stacked research combination.

  • CJC-1295 DAC: For specific details, please contact us on Telegram.
  • Ipamorelin: For availability or additional research information, please contact us on Telegram.
  • Support: Additional information is available upon request.
  • Important: This content is not intended as medical advice, treatment guidance, or usage instruction.
  • Storage Instructions

Proper storage preserves peptide integrity and quality.

  • Label Information: Please follow the provided label or packaging instructions for proper storage.
  • Research Details: For storage-related or handling-related information, please contact us on Telegram.
  • Handling Note: Keep information and handling details consistent with the provided documentation.
  • Important: This content is not intended as medical advice, usage guidance, treatment guidance, or usage instruction.
  • Important Notes

Practical considerations for consistency and safety.

  • Research Details: For specific information, please contact us on Telegram.
  • Information: For additional details, please contact us directly.
  • Availability: Availability information is available upon request.
  • Important: This content is not intended as medical advice, usage guidance, treatment guidance, or treatment recommendation.
  • How This Works
This section provides general research information about CJC-1295 DAC and Ipamorelin for educational and research reference only. The content is intended to help visitors understand the research category in a simple and organized way. This information should not be considered medical advice, treatment guidance, usage guidance, or usage instruction. For additional details or availability information, please contact us on Telegram.
  • Potential Benefits & Side Effects

Observations from preclinical and clinical literature on GH secretagogues.

  • Body composition: GH secretagogues have demonstrated improvements in lean mass and reductions in fat mass in clinical studies.
  • Sustained GH/IGF-1 elevation: CJC-1295 DAC has been studied for effects related to growth hormone pathway activity.
  • Selectivity: Ipamorelin has been studied for its interaction with growth hormone-related pathways.
  • Tolerability: Research studies have evaluated tolerability and reported observations related to these compounds.
  • Water retention, mild headache, and transient sensations have been reported in studies involving GH-related compounds.
  • Lifestyle Factors

Complementary strategies for optimal outcomes.

  • Nutrition: Pair with a balanced, protein-forward diet tailored to individual energy and recovery needs.
  • Exercise: Combine resistance training and aerobic activity to support healthy adaptations.
  • Sleep: Prioritize 7–9 hours of quality sleep; GH secretion is commonly associated with deep sleep.
  • Stress Management: Manage stress and avoid chronic caloric restriction, which can affect GH response.
  • Research Handling Information

General research handling information for educational and research reference only.

  • Handling Information: Please follow the provided label or packaging instructions for general handling information.
  • Research Details: For specific details, please contact us on Telegram.
  • Additional Information: For further information, please contact us directly.
  • Important: This content is not intended as medical advice, treatment guidance, usage guidance, or research instructions.
  • Research Information
We provide general research information and educational references.

Why Vitality Labs?

  • Quality Information: General research information and support.
  • Research Details: Additional information is available upon request.
  • Contact: For more information, please contact us on Telegram.
Contact on Telegram
  • Important Note

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or clinical guidance.

  • References

Journal of Clinical Endocrinology & Metabolism

— Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
More Info

European Journal of Endocrinology

— Ipamorelin, the first selective growth hormone secretagogue
More Info

Endocrine Reviews

— Growth hormone secretagogues: mechanisms and clinical applications
More Info

Sleep Medicine Reviews

— Sleep and the GH/IGF-1 axis: physiological and clinical implications
More Info

Bachem

— Handling and storage guidelines for peptides (lyophilized stability)

More Info

Bachem

— Reconstituted peptide storage and stability recommendations
More Info

Translational Andrology and Urology (PMC)

— GH secretagogues in body composition management for hypogonadal males
More Info

International Journal of Surgery (PubMed)

— Ipamorelin for postoperative ileus: tolerability and safety in bowel resection patients
More Info

NCBI Bookshelf

— Parenteral medication administration: subcutaneous technique
More Info

CDC

— Vaccine administration guidelines: subcutaneous route (no aspiration required)
More Info

Growth Hormone & IGF Research (ScienceDirect)

— Ipamorelin induces longitudinal bone growth in rats
More Info

Physiological Reviews

— The somatotropic axis: GH and IGF-1 regulation and actions
More Info

Clinical Drug Investigation (PMC)

— Subcutaneous drug delivery: pharmacokinetic considerations
More Info

NCBI Bookshelf

— Best practices for Research (asepsis, preparation, and administration)
More Info

Contact on Telegram Peptides

— BPC-157 + TB-500 (10 mg blend) page (quality and batch documentation)
More Info